Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor. Interleukin 6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Read more in the app

Effectiveness of tocilizumab in patients hospitalized with COVID-19

Repurposing tocilizumab in scleroderma patients may prevent early lung disease

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab